PE20210377A1 - Anticuerpos anti-pd-l1 y usos de los mismos - Google Patents
Anticuerpos anti-pd-l1 y usos de los mismosInfo
- Publication number
- PE20210377A1 PE20210377A1 PE2020001301A PE2020001301A PE20210377A1 PE 20210377 A1 PE20210377 A1 PE 20210377A1 PE 2020001301 A PE2020001301 A PE 2020001301A PE 2020001301 A PE2020001301 A PE 2020001301A PE 20210377 A1 PE20210377 A1 PE 20210377A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- antibodies
- fragments
- cdr1
- cdr2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- G01N33/575—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70532—B7 molecules, e.g. CD80, CD86
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invencion se refiere a anticuerpos anti-PD-L1 o fragmentos de los mismos que se unen especificamente al dominio C de inmunoglobulina de la proteina PD-L1, en particular los residuos de aminoacidos Y134, K162 y N183. En varios ejemplos, los anticuerpos o fragmentos de los mismos incluyen una VH CDR1 de la SEQ ID NO: 1, una VH CDR2 de la SEQ ID NO: 116, una VH CDR3 de la SEQ ID NO: 117, una VL CDR1 de la SEQ ID NO: 4, una VL CDR2 de la SEQ ID NO: 5, y una VL CDR3 de la SEQ ID NO: 6, o variantes de cada uno de los mismos, utiles en el tratamiento y diagnostico de enfermedades tales como cancer y enfermedades infecciosas. Tambien se refiere a anticuerpos biespecificos, metodos de tratamiento y composiciones que comprende el anticuerpo o fragmentos de los mismos
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018081079 | 2018-03-29 | ||
| PCT/CN2019/080458 WO2019185029A1 (en) | 2018-03-29 | 2019-03-29 | Anti-pd-l1 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20210377A1 true PE20210377A1 (es) | 2021-03-02 |
Family
ID=68060946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020001301A PE20210377A1 (es) | 2018-03-29 | 2019-03-29 | Anticuerpos anti-pd-l1 y usos de los mismos |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11220546B2 (es) |
| EP (1) | EP3589660A4 (es) |
| JP (1) | JP7124257B2 (es) |
| KR (2) | KR102177931B1 (es) |
| CN (1) | CN110891975B (es) |
| AU (1) | AU2019241339B2 (es) |
| BR (1) | BR112020019827A2 (es) |
| CA (1) | CA3086434C (es) |
| CL (1) | CL2020002223A1 (es) |
| EA (1) | EA202091590A1 (es) |
| IL (1) | IL275734B (es) |
| MX (1) | MX2020007842A (es) |
| MY (1) | MY188237A (es) |
| PE (1) | PE20210377A1 (es) |
| PH (1) | PH12020551173A1 (es) |
| SG (1) | SG11202006008WA (es) |
| UA (1) | UA125918C2 (es) |
| WO (1) | WO2019185029A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018015584A (es) * | 2016-06-13 | 2019-09-18 | I Mab | Anticuerpos anti-pd-l1 y usos de los mismos. |
| WO2020020307A1 (en) * | 2018-07-25 | 2020-01-30 | I-Mab Biopharma Co., Ltd. | Anti-cd73 anti-pd-l1 bispecific antibodies |
| AU2019326635B2 (en) * | 2018-08-21 | 2024-05-23 | Abl Bio Inc. | Anti-PD-L1/anti-LAG3 bispecific antibodies and uses thereof |
| WO2021097800A1 (en) * | 2019-11-22 | 2021-05-27 | Abl Bio Inc. | Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof |
| CN115643797A (zh) * | 2020-04-30 | 2023-01-24 | 天境生物科技(上海)有限公司 | 包含抗cd47抗体的药物组合物 |
| CN121319180A (zh) * | 2020-07-28 | 2026-01-13 | 乐普生物科技股份有限公司 | 靶向PD-L1和TGF-β的双功能分子 |
| KR20230166150A (ko) | 2020-08-19 | 2023-12-06 | 젠코어 인코포레이티드 | 항-cd28 조성물 |
| CN114195900B (zh) * | 2020-09-17 | 2024-02-23 | 普米斯生物技术(珠海)有限公司 | 一种抗4-1bb/pd-l1双特异性抗体及其用途 |
| CN114316045B (zh) * | 2020-09-29 | 2024-07-12 | 英诺欧奇生物医药(苏州)有限公司 | 抗pd-l1抗体及其用途 |
| CN113234162B (zh) * | 2020-12-24 | 2022-05-13 | 四川大学华西医院 | 一种靶向cd133的嵌合抗原受体t细胞 |
| EP4276466A4 (en) * | 2021-01-08 | 2024-12-18 | Beijing Hanmi Pharmaceutical Co., Ltd. | ANTIBODY SPECIFICALLY BINDING WITH PD-L1 AND ANTIGEN-BINDING FRAGMENT OF ANTIBODY |
| BR112023016706A2 (pt) * | 2021-02-19 | 2023-10-31 | Seoul Nat Univ R&Db Foundation | Anticorpo ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, métodos para produzir um anticorpo ou um fragmento de ligação ao antígeno do mesmo e para detectar agrupamento de diferenciação 47 ou determinar uma quantidade de agrupamento de diferenciação 47 em uma amostra, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo |
| CN115073599B (zh) * | 2021-03-16 | 2023-04-28 | 北京天广实生物技术股份有限公司 | 结合pd-l1的抗体及其用途 |
| CA3252619A1 (en) | 2022-02-23 | 2023-08-31 | Xencor, Inc. | Anti-CD28 and anti-PSMA antibodies |
| US20250215089A1 (en) * | 2022-04-02 | 2025-07-03 | Harbour Biomed (Shanghai) Co., Ltd | Antigen-binding protein targeting pd-l1 and cd40, preparation therefor, and use thereof |
| EP4619439A1 (en) * | 2022-11-15 | 2025-09-24 | TJ Biopharma (Shanghai) Co., Ltd. | Anti-pd-l1 nanobodies |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2161336T5 (pl) * | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| WO2011043194A1 (en) | 2009-10-09 | 2011-04-14 | Semiconductor Energy Laboratory Co., Ltd. | Semiconductor device and method for manufacturing the same |
| WO2015112534A2 (en) * | 2014-01-21 | 2015-07-30 | Medimmune, Llc | Compositions and methods for modulating and redirecting immune responses |
| CN110156892B (zh) | 2014-07-03 | 2023-05-16 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
| LT3789402T (lt) * | 2014-11-20 | 2022-09-26 | F. Hoffmann-La Roche Ag | Kompleksinė terapija, naudojant t ląsteles aktyvinančias bispecifines antigeną surišančias molekules ir pd-1 ašį surišančius antagonistus |
| CN105777906B (zh) * | 2014-12-19 | 2019-04-23 | 苏州丁孚靶点生物技术有限公司 | 抗pd-l1全人抗体及其应用 |
| CN106939047B (zh) * | 2016-01-04 | 2021-08-31 | 江苏怀瑜药业有限公司 | 一种pd-l1抗体及其制备方法 |
| MX2018015584A (es) * | 2016-06-13 | 2019-09-18 | I Mab | Anticuerpos anti-pd-l1 y usos de los mismos. |
| CN107488229B (zh) * | 2016-06-13 | 2020-11-17 | 天境生物科技(上海)有限公司 | Pd-l1抗体及其用途 |
| CN108777906B (zh) | 2018-06-25 | 2020-06-16 | 珠海惠尔益电子科技有限公司 | 一种双灯组变焦电路及头灯 |
| WO2020020307A1 (en) * | 2018-07-25 | 2020-01-30 | I-Mab Biopharma Co., Ltd. | Anti-cd73 anti-pd-l1 bispecific antibodies |
| AU2019390274A1 (en) * | 2018-11-30 | 2021-07-22 | Abl Bio Inc. | Anti-PD-L1/anti-4-1BB bispecific antibodies and uses thereof |
-
2019
- 2019-03-29 WO PCT/CN2019/080458 patent/WO2019185029A1/en not_active Ceased
- 2019-03-29 AU AU2019241339A patent/AU2019241339B2/en active Active
- 2019-03-29 KR KR1020197031498A patent/KR102177931B1/ko active Active
- 2019-03-29 EP EP19769368.2A patent/EP3589660A4/en active Pending
- 2019-03-29 EA EA202091590A patent/EA202091590A1/ru unknown
- 2019-03-29 SG SG11202006008WA patent/SG11202006008WA/en unknown
- 2019-03-29 JP JP2019553005A patent/JP7124257B2/ja active Active
- 2019-03-29 KR KR1020207032104A patent/KR102475106B1/ko active Active
- 2019-03-29 BR BR112020019827-7A patent/BR112020019827A2/pt unknown
- 2019-03-29 MX MX2020007842A patent/MX2020007842A/es unknown
- 2019-03-29 CA CA3086434A patent/CA3086434C/en active Active
- 2019-03-29 PE PE2020001301A patent/PE20210377A1/es unknown
- 2019-03-29 MY MYPI2020003980A patent/MY188237A/en unknown
- 2019-03-29 US US16/610,071 patent/US11220546B2/en active Active
- 2019-03-29 UA UAA202005634A patent/UA125918C2/uk unknown
- 2019-03-29 CN CN201980003429.7A patent/CN110891975B/zh active Active
-
2020
- 2020-06-29 IL IL275734A patent/IL275734B/en unknown
- 2020-08-02 PH PH12020551173A patent/PH12020551173A1/en unknown
- 2020-08-28 CL CL2020002223A patent/CL2020002223A1/es unknown
-
2021
- 2021-12-28 US US17/563,502 patent/US20220119531A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US11220546B2 (en) | 2022-01-11 |
| AU2019241339A1 (en) | 2019-11-14 |
| JP7124257B2 (ja) | 2022-08-24 |
| IL275734B (en) | 2022-06-01 |
| BR112020019827A2 (pt) | 2021-01-05 |
| CA3086434A1 (en) | 2019-10-03 |
| UA125918C2 (uk) | 2022-07-06 |
| CN110891975A (zh) | 2020-03-17 |
| WO2019185029A1 (en) | 2019-10-03 |
| EP3589660A4 (en) | 2021-04-07 |
| EP3589660A1 (en) | 2020-01-08 |
| MX2020007842A (es) | 2020-09-25 |
| KR102475106B1 (ko) | 2022-12-08 |
| KR102177931B1 (ko) | 2020-11-13 |
| US20220119531A1 (en) | 2022-04-21 |
| KR20190128716A (ko) | 2019-11-18 |
| CN110891975B (zh) | 2023-11-10 |
| EA202091590A1 (ru) | 2021-01-21 |
| MY188237A (en) | 2021-11-24 |
| KR20200130747A (ko) | 2020-11-19 |
| JP2020518233A (ja) | 2020-06-25 |
| AU2019241339B2 (en) | 2021-08-12 |
| CL2020002223A1 (es) | 2021-01-29 |
| PH12020551173A1 (en) | 2021-05-31 |
| SG11202006008WA (en) | 2020-07-29 |
| NZ758371A (en) | 2024-10-25 |
| CA3086434C (en) | 2024-01-09 |
| US20200157222A1 (en) | 2020-05-21 |
| IL275734A (en) | 2020-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20210377A1 (es) | Anticuerpos anti-pd-l1 y usos de los mismos | |
| CO2018013500A2 (es) | Anticuerpos anti-pd-l1 y usos de los mismos | |
| MX2019008758A (es) | Anticuerpos anti-cd37 y usos de los mismos. | |
| HRP20240719T1 (hr) | Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba | |
| HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
| AR109715A1 (es) | Anticuerpos anti-cd27 | |
| ECSP18043564A (es) | Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas | |
| CO2017005738A2 (es) | Anticuerpos anti-pd-1 | |
| AR106991A1 (es) | Anticuerpos neutralizantes del virus de inmunodeficiencia humana | |
| NZ625403A (en) | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration | |
| AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
| MX2017001531A (es) | Anticuerpos anti-trem2 y metodos de uso de los mismos. | |
| PE20221580A1 (es) | Anticuerpos terapeuticos y sus usos | |
| WO2017152102A3 (en) | Anti-trem1 antibodies and methods of use thereof | |
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| RU2019119862A (ru) | Антитела к компоненту комплемента c5 | |
| EA201491851A1 (ru) | Композиции и способы для лечения болезни альцгеймера | |
| PH12017500699A1 (en) | Antibodies that bind to ccr6 and their uses | |
| JP2016530223A5 (es) | ||
| FI3515947T3 (fi) | Uudet tekijän XI vasta-aineet ja niiden käyttökohteet | |
| MX2020006155A (es) | Moleculas de union a cd-16 biespecificas y su uso en el tratamiento de enfermedades. | |
| EA202190495A1 (ru) | Антитела против pd-l1 человека | |
| PE20190633A1 (es) | Anticuerpos anti-gm-csf y usos de los mismos | |
| AR107083A1 (es) | Anticuerpos dirigidos a cd32b y métodos de uso de los mismos |